Physician profile
Kenneth D Chi
NPI 1821070939
$13,156.30
in general payments reported to CMS, 2019-2025
36 companies · $2,580 in 2025
The $2,580 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,024 · 2020: $3,009 · 2021: $562 · 2022: $136 · 2023: $1,019 · 2024: $826 · 2025: $2,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946 · Consulting Fee: $875 · Travel and Lodging: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.59 |
| Consulting Fee | $875.00 |
| Travel and Lodging | $604.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,521.88 | 2019-2025 | Axios, Acquire, General - Biliary Devices |
| Olympus Medical Systems Corporation | $875.00 | 2025 | Evis Exera III Duodenovideoscope |
| Abbvie INC. | $866.76 | 2019-2025 | Linzess, Creon, Viberzi |
| Janssen Biotech, INC. | $463.78 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $203.00 | 2020-2025 | Entyvio |
| Cook Medical LLC | $201.82 | 2020-2023 | Hemospray |
| Allergan, INC. | $167.01 | 2019-2020 | |
| Qol Medical, LLC | $155.90 | 2019-2025 | Sucraid, Sucraid |
| Ambu INC. | $153.22 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $153.00 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $150.28 | 2023-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.56 | 2019-2024 | Xifaxan, Plenvu |
| Endogastric Solutions, INC | $107.51 | 2023 | Esophyx |
| Pfizer INC. | $102.19 | 2019-2025 | |
| Lilly USA, LLC | $87.97 | 2023-2025 | Omvoh |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $74.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $68.52 | 2019-2023 | Dificid |
| Ardelyx, INC. | $64.75 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $64.57 | 2021-2024 | Gi Genius |
| Genzyme Corporation | $61.45 | 2023 | |
| Celgene Corporation | $60.23 | 2022-2023 | Zeposia |
| Braintree Laboratories, INC. | $58.55 | 2020-2023 | Sutab, Suflave |
| Digestive Care, INC. | $44.86 | 2023-2024 | Pertzye |
| Phathom Pharmaceuticals, INC. | $43.33 | 2024 | Voquezna |
| Gilead Sciences, INC. | $41.07 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $36.79 | 2024 | Dupixent |
| Vivus LLC | $36.14 | 2023-2025 | Qsymia |
| Ethicon US, LLC | $33.00 | 2019 | |
| W. L. Gore & Associates, INC. | $19.38 | 2023 | Gore Cardioform Septal Occluder |
| Glaxosmithkline, LLC. | $19.33 | 2025 | |
| Daiichi Sankyo INC. | $17.39 | 2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $16.33 | 2024 | Rebyota |
| Micro-Tech Endoscopy USA, INC. | $14.61 | 2021 | |
| Mauna Kea Technologies, INC. | $13.25 | 2019 | |
| Romark Laboratories, Lc | $12.76 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$40,341.03 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.